- Home
- ZURA vs GALT Comparison
ZURA vs GALT Comparison
Compare ZURA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | GALT |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZURA | GALT |
|---|---|---|
| Price | $4.31 | $4.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $11.38 | $8.50 |
| AVG Volume (30 Days) | 369.0K | ★ 714.1K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.73 |
| 52 Week High | $4.68 | $7.13 |
Technical Indicators
Market Signals| Indicator | ZURA | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 33.92 |
| Support Level | $3.88 | $3.80 |
| Resistance Level | $4.45 | $7.13 |
| Average True Range (ATR) | 0.25 | 0.72 |
| MACD | 0.05 | -0.19 |
| Stochastic Oscillator | 89.36 | 6.91 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.